U.S. Markets closed

Venaxis, Inc. (APPY)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.94-0.01 (-0.25%)
At close: 5:00PM EDT
People also watch
Interactive chart
Previous Close3.95
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 months ago

    Colorado biotech cutting employees, exploring 'strategic alternatives'

    In September , Venaxis Inc., a Castle Rock medical device company, acquired Bioptix Diagnostics Inc. of Boulder and renamed itself Bioptix Inc. T hat acquisition quickly turned nasty with a major shareholder accusing company executives of "an inside management job," with executives firing back at the shareholder. And earlier this month after the 2016 drama, Bioptix shook up its board and said three of its board members are leaving, including the former lieutenant governor of Colorado.

  • PR Newswire6 months ago

    Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to "BIOP" from "APPY"

    BOULDER, Colo., Dec. 8, 2016 /PRNewswire/ --  Venaxis®, Inc. (Nasdaq: APPY), announced that following the approval from shareholders at the 2016 Annual Meeting of Shareholders of the proposal to change ...

  • Venaxis, Inc. :APPY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
    Capital Cube6 months ago

    Venaxis, Inc. :APPY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016

    Categories: Yahoo Finance Get free summary analysis Venaxis, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Venaxis, Inc. – Vermillion, Inc., Chembio Diagnostics, Inc., OraSure Technologies, Inc., Alere Inc., Echo Therapeutics, Inc., American Bio Medica Corporation and Myriad Genetics, Inc. (VRML-US, CEMI-US, OSUR-US, ALR-US, ECTE-US, ... Read more (Read more...)